Diskussion:Cell Specific Cancer Therapy
Killing Cancer Cells With Magnetic Energy by Richard Leviton Cancer cells can be precisely targeted and destroyed by physicians using an energy beam at this innovative cancer center in the Dominican Republic.
Every day a few cancer cells are formed in the human body. If the immune system is working efficiently, these cancer cells are of no consequence or threat to one's health. It's a transient event in life-as-usual inside the healthy human body with its approximately one trillion cells.
The immune system's specialized defense cells such as lymphocytes and natural killer cells will destroy the aberrant cells, and no cancerous tumor will ever grow. But if the immune system is compromised through faulty diet, inadequate nutrition, too many toxins, harmful energies—at least 33 potential carcinogenic factors have been identified—then it is possible for these few naturally-occurring cancer cells to remain and form a cluster, and from this, to multiply into a tumor.
Conventional equipment for detecting cancers in the body is only able to identify them when they are relatively large and already dangerous. But what if there were a scanning device that could pinpoint the tiniest amounts of newly generated cancer cells anywhere in the body, marking their precise location like blips on a radar screen? And what if there were another noninvasive device that was able to target these minute cancer clusters (or tumors, if necessary) and kill them quickly with a beam of energy?
It sounds fantastic, the kind of notion that science fiction writers might envision for the medicine of a far-off future. Yet, according to John Armstrong and Michael Reynolds, directors of the Center for Cell Specific Cancer Therapy in Santo Domingo, in the Dominican Republic, that is precisely what their year-old treatment center is offering cancer patients.
Armstrong, originally from Orem, Utah, and now based in Santo Domingo, is a former cancer patient successfully treated by this therapy, while Reynolds is a businessman who commutes regularly from his home in San Francisco, California, to the Caribbean center. Their cancer treatment approach is simple yet radical: kill the cancer cells with magnetic energy from the CSCT-200.
According to Armstrong and Reynolds, since opening their Center doors on August 13, 1996, the technique has successfully reversed cancers in more than 50% of their 150 clients by targeting only cancer cells and destroying them with a pulsed electromagnetic field. Not only were these cancers reversed, there was no detectable cancer remaining in the body.
While the Center does not claim to "cure" cancer, Reynolds says the therapy "is designed to reliably kill active cancerous cells in a patient's body, even after metastasis has occurred and even in Stage IV cancers, without causing any damage to healthy cells. There are no side effects and no aftereffects." Armstrong and Reynolds are so confident that their technology can kill cancer cells and reverse tumors that they refund the entire fee to any patient who doesn't respond to the initial treatment within the first few days.
Exploiting Cancer's Uniqueness
The Center's device is able to detect and specifically target cancer cells by taking advantage of a unique condition of cancer cells. They have an atypical metabolism, says Richard Liang, Ph.D., the Center's resident physicist, director of research and development, and the expert responsible for fine-tuning the equipment. Dr. Liang holds a doctorate in nuclear engineering from Columbia University in New York.
All cells, including cancerous ones, constantly undergo metabolism, which is the processing of foods and nutrients to release energy and water. In this process, there are electrical activities, in which positive and negative ions flow in and out of cells across the cell membrane in a state of equilibrium. This flow is called the ionic channel; the ability of a healthy cell to keep things in balance is called membrane potential.
While normal, healthy cells require approximately 30 steps to complete their metabolic processes, cancer cells take many short cuts, and complete theirs in about four. Normal cells, (which are aerobic, using oxygen) make use of at least 90% of their nutrients, but cancer cells (which are anaerobic, operating without oxygen) are highly wasteful, crude, and inefficient metabolizers, leaving behind about 80% of the raw materials.
Perhaps as a result of this, they give off an excessive amount of ions, far more than normal cells. It is this excessive ionization that the Center's device is able to pinpoint, explains Dr. Liang. The excess ionic products of the cancer cells are positively charged. Positive ions produce that stultifying, energy-dampening feeling in the atmosphere just before a thunderstorm or in a stuffy, poorly ventilated office.
The following analogy may make this clearer. Consider that you are observing, through an infrared tracking device, a person calmly eating lunch. Through the infrared lens, you see a steady orange nimbus six inches thick around the person; this is a picture of the heat emanations from the person's body. Analogically, this represents the picture of a healthy cell.
Now let's observe a second person eating lunch, except this one is highly agitated, anxious, and full of temper. The infrared image shows a much bigger heat aura around the person. It is pulsating bright red and rays dart out sporadically. This represents the image of a cancer cell, and it is detectable by the special electromagnetic sensing device used at the Center for Cell Specific Cancer Therapy.
"The atypical metabolic system used by cancer cells is like a beacon that enables us to target them," Reynolds explains. "Nothing else in the human body produces that energy signature." As Dr. Liang explains, the cancer's distinctive way of processing nutrients produces excessive amounts of ionic product and these collectively emit detectable energy which the Center's scanning device picks up as a signal that cancer cells exist.
Targeting Cancer Cells Only
The scanning procedure is simple and relatively quick, says Reynolds. The patient wears a surgical robe and lies on a table; the doctor positions the Cell Specific Cancer Therapy (CSCT) scanning device over different parts of the body, moving from head to foot, scanning the body in lateral segments. Usually, the body is scanned in zones about twelve inches wide.
Over the months, Reynolds' team has been building up an inventory of cancer signals and scanning frequencies, a bit like coming to know the names and locations of individual radio stations on an AM/FM radio dial. A lymphoma cell (cancer of the lymph system) will have a slightly different beacon signal from a melanoma (skin cancer). This inventory enables the CSCT operator to fine-tune the scanning beam according to body location or type of cancer.
Patients feel nothing nor are they confined in a potentially claustrophobic scanning chamber as with magnetic resonance imagings (MRIs). The CSCT device, which resembles an elevated donut-shaped ring (five inches thick) set on moveable tracks, is slowly moved over and down a patient's body. "With the CSCT device, the patient will not have any sense of being enclosed or surrounded," says Reynolds.
The physician marks the cancerous sites—the device does not quantify how many cancer cells, so it could be 40 or 40,000 in a given location—on a generic body chart and by magic marker pinpoints on the patient's skin. When cancer cells are pinpointed, the device makes a beep; when the cancer cells have been killed, there is no beep.
The CSCT device not only scans the body for cancer cells, it delivers the killing blow that destroys them. Physicists (and mystics) know that all matter is energy at varying rates of vibration or frequency. A healthy liver cell vibrates at a specific, distinctive frequency, just as a cancerous liver cell vibrates at its own measurable frequency. The CSCT device identifies the sound (or frequency) of the cancer cells, matches it precisely, and sends it back to the cells.
As Dr. Liang explains, this introduces chaos into the cancer cells; they become unstable, begin to vibrate at irregular rates, rupture, and fall apart, dead. The process is poetically similar to the famous Biblical image of tumbling the walls of Jericho by precisely targeted sound. But the destructive process is completely specific to the targeted cancer cells; healthy cells are unaffected by the killing beams of CSCT electromagnetic energy, says Dr. Liang.
"The strength of the CSCT device lies in its ability to give the operator instantaneous feedback: it tells us when we're on target and being effective—when we've killed cancer cells." Treatments last about 30 minutes, and are usually given twice daily with a five-hour rest interval. Patients typically spend up to three weeks receiving treatments, staying at nearby hotels as the Center is set up only for outpatients, Reynolds explains.
When the full-body CSCT scan reveals no more signs of active cancer in a single scanning session (and further testing, including independent blood work, has confirmed these results), the treatment is deemed complete and patients are sent home. It may take the body some time to process and eliminate the now dead cancer mass, so the patient has to deal, temporarily, with the paradoxical situation of still having a sometimes palpable tumor mass yet being free of active, life-threatening cancer.
"We've observed that different patients heal at different rates, so the after-treatment state can vary considerably among patients," Reynolds explains. "Some people with a large tumor will not show any signs of tumor reduction at the Center, yet their cancer markers (according to laboratory blood tests) will decrease and their CSCT scans will come clear. It can take several months for the tumor to be dissolved by the body."
While CSCT can usefully treat patients who have had chemotherapy and radiation, the technique cannot "see" and therefore cannot treat those cancer cells which have received sub-lethal doses of chemotherapy or radiation, says Reynolds. These toxic procedures do not kill all cancer cells but rather slow down their metabolism so much as to render the cancer cells metabolically inactive and functionally invisible to the CSCT scan.
"It's almost as if the cancer cells are put in a state of suspended animation," Reynolds comments. Put in another way, chemotherapy and radiation certainly kill some cancer cells, but not all of them. Many are simply "wounded." "If a cancer cell receives a sub-lethal dose of chemotherapy or radiation, like a felled boxer, it's down for the count—but not necessarily out." If all chemotherapy does is slow down a cancer cell's metabolism, this casts serious doubt on the validity of chemotherapy-induced remissions. "Remission means we can't find anything right now; the cancer is either dead or sleeping, but we don't know which."
Seemingly, by definition, a remission obtained this way is sure to be short-lived, Reynolds speculates. "This means that chemo-therapy and radiation treatments are going to leave a time bomb behind in the patient's body, and nobody knows how long the fuse is or when the cancer will come back."
But in many cases the cancers do grow back, as evidenced by chemo-therapy's abysmally poor five-year average success rate of about 7%. CSCT physicians have to wait until the chemotherapy or radiation effects wear off and the cancer cells become metabolically active again before they can decisively kill them with CSCT energy. In effect, chemotherapy and radiation treatments get in the way of killing cancer with CSCT. However, often a patient has some "dormant" cancer and some active cancer that chemotherapy has missed, or that grew after treatment. Having had chemotherapy does not block the effect of CSCT on the active cancer cells.
The type or severity of the cancer does not determine if CSCT can be used, says Reynolds. Patients with seriously metastasized Stage IV cancers can be successfully treated. The type of patient that the Center, reluctantly, must turn away, is the one requiring sophisticated or emergency medical care, such as blood transfusions, or patients with internal bleeding, grossly enlarged internal organs, or other conditions requiring around-the-clock medical care, says Reynolds. "We can deal with the cancer, but we are not equipped to treat all the other collateral damage a patient may present," Reynolds confides.
Even for the cancer patient who has already received all conventional treatments without benefit, whose cancer has progressed to Stage IV, and who is facing imminent death, "CSCT can grab hold of them and pull them back from the edge," Reynolds states.
Reynolds estimates that 80% of patient applications are accepted for CSCT treatment, and of these, 20% drop out of the program because the approach does not work for their cancer. "If the treatment is going to work for a patient, it will stop the growth of the cancer usually with the first treatment, and then it's only a matter of regressing it."
The Center's medical director, Ariel Antonio Perez Ubiera, M.D., concurs. "We kill cancer in place. We are not cutting it away. We are only changing its growing characteristics. Usually it takes a while to see a reduction in tumor mass. But it very often happens that when you take an MRI before and after treatment you see one of two things. Either the tumor stops growing or it actually decreases in size. Either is a positive sign that the therapy is working."
Reversing Stage III Ovarian Cancer
One of the Center's first patients was Mara, age 40, who flew from New York to Santo Domingo for treatment of her Stage III ovarian cancer.
Mara had entered surgery in Mount Sinai Hospital in New York in early July of 1996 for treatment of what doctors believed to be a large ovarian cyst; it was only during surgery that they discovered it was a tumor instead. There was also a tumor growing on the pelvic wall. The surgeons performed a radical hysterectomy, removing all of Mara's uterus and both ovaries, and put her on large doses of antibiotics.
The cancer discovery was a shock because, other than having a self-described "massive appetite" and looking somewhat drawn and tired and sometimes feeling unusually exhausted, Mara had had no cancer-identifying symptoms. On the other hand, cancer was in her family, as her mother had died in her forties of breast cancer.
Mara had had regular mammograms for the previous five years and had been seeing a gynecologist twice yearly for checkups since the age of 15 and recently to monitor the status of fibroids in her uterus. "I don't think anyone could have looked after themselves more than I did, yet the doctors still missed my cancer. I felt very let down by the medical establishment."
Seven days after her surgery, Mara submitted to a round of chemotherapy with taxol and carboplatin, "but it didn't feel right," she says. "I couldn't believe in poisoning my body to effect a cure. It didn't make any sense." Her doctors gave her about a 20% chance of survival with the chemotherapy. Mara cancelled the chemotherapy after one day of experiencing its poisonous effects.
Mara was already acquainted with alternative cancer therapies, and for a short while took Haelan 851 (a liquid fermented soybean concentrate) and hydrazine sulfate (a synthesized substance). These are two alternative anticancer agents that are often effective in strengthening the immune system (Haelan) or halting weight loss from cancer (hydrazine sulfate). In Mara's opinion, these substances "bolstered my body."
About seven weeks after her surgery, Mara learned about the Center for Cell Specific Cancer Therapy and boarded a plane for Santo Domingo to begin treatment. "I felt very strongly about this approach because it is completely noninvasive. I think it's the cancer technology of the future."
After Dr. Ubiera performed the first whole-body scan on her, using a purple felt-tipped pen to mark on her skin the site of cancer cells in her body, "I looked like I had measles," Mara recalls. "It was discouraging. The surgeons thought they had removed all the cancer, yet here was all this additional cancer in my body."
The scan indicated Mara's cancer had spread to her lymphatic system; the next day, Dr. Ubiera began Mara's first treatment. "I didn't feel anything, no side effects whatsoever, and I was not tired afterwards, either," says Mara. She had 14 treatments over the course of ten days, after which she scanned clear. This meant Mara's cancer was not only reversed, but dead. Dr. Ubiera cross-checked Mara's progress with frequent blood and urine tests, which gradually cleared of any signs of cancer as well.
In November of that year, Mara returned to her gynecological oncologist and reported her results. He was entirely noncommittal and asked her nothing about the CSCT procedure, says Mara. "It was amazing. I guess he couldn't jeopardize his position by expressing interest in the technique."
But the doctor couldn't deny the evidence of a sonogram that day that showed Mara completely free of cancer. Every month since her CSCT, Mara has had a CA125 blood test, which is a standard cancer marker analysis for ovarian cancer; each time it has tested clear of any signs (or markers) of cancer.
"If I'd known about CSCT before my surgery, I never would have gone through with the operation," she states. "That's how much I believe in it. This could make everything else in the world of cancer treatments obsolete." In mid-April 1997, physicians at the Mount Sinai Hospital in New York City declared Mara "disease free."
Not Another Pale-Faced, Bald-Headed Chemo Patient
In December 1996, April, age 14, was diagnosed with a type of invasive cancer called "Pelvic Ewings sarcoma non-osseous." The tumor was growing on the inside of her peritoneum, which is the membrane lining separating the internal organs from the ribs and muscles. At the time of her first ultrasound, April had an abdominal tumor that was visibly bulging; her parents had hoped it was only a large ovarian cyst, but it was cancer.
The symptoms of cancer had been appearing one by one over the previous nine months, according to April's mother, Mary Ann. April couldn't get a tan in the summer months, she lost weight, dropping down to 80 pounds, had fevers twice a month, suffered back pains, and felt tired all the time.
The day after receiving the diagnosis, April underwent surgery at Yale-New Haven Children's Hospital in Connecticut, during which a grapefruit-sized tumor was removed from her pelvic area, where it had attached itself to her pubic bone and bladder. April was left with an eight-inch scar. The surgeons said they had excised about 98% of the tumor, but that they were unable to remove the remaining 2%. They labeled it a "contained tumor," with cancer showing up nowhere else in the body.
April's oncologist started putting pressure on the family to agree to chemotherapy, but Mary Ann wanted more time to seek second opinions and think about her options. The oncologists gave Mary Ann two weeks to consider her alternatives before turning up the heat on her to begin April's chemotherapy and radiation. In fact, Mary Ann says the medical authorities "harassed" the family to start the chemotherapy, even threatening to file a negligence complaint with the state of Connecticut. Mary Ann left it to her husband to fend off the oncologists (these matters were eventually straightened out) while she took April to Santo Domingo for CSCT treatment.
According to Dr. Ubiera, April underwent 18 CSCT treatments over a 17-day period in January, 1997. The initial scans showed that April had cancer cells all over her pelvic area, on her left leg, her back, and her hand. "If left untreated, I'm sure April's cancer would have grown back," says Mary Ann.
The family's religious beliefs precluded blood transfusions and therefore chemotherapy because it often requires transfusions, so learning about CSCT and getting quickly scheduled for treatment was a stroke of good fortune. "The important issue is that the medical field could not offer us the best possible care to meet with our daughter's strong religious convictions, so it was necessary for us to search for an alternative treatment which would allow for them."
Three months later, in April, 1997, an MRI and CT bone scan at Rhode Island Hospital Department of Diagnostic Imaging in Providence showed "no evidence of bony metastatic disease," no sign of cancer in the chest, abdomen, or pelvis, and "normal activity throughout the skeleton." While at the hospital, April and her mother found themselves in the midst of 14 children milling about. Each had a bald head and a very pale, whitish complexion—two of the standard side effects of chemotherapy.
Mary Ann comments on that visit: "I kept saying to myself, why can't they just get a CSCT machine in here and help these kids? Why put them through all this? It was very sad. I felt almost guilty sitting there with a nicely tanned, healthy teenager who was spared all of this."
According to the surgeon who had removed the original tumor, April was "free from any new disease in her pelvis." On July 19, 1997, Mary Ann stated that "almost eight months from the surgery, there has been no recurring growth of cancer. April has no symptoms at all, no pain, nothing, her energy level is excellent, and she has regained 17 pounds."
CSCT Treatments
The CSCT device (which focuses magnetic fields) not only scans the body for cancer cells, it delivers the killing blow that destroys them. After 14 CSCT treatments, Mara was free of her Stage III Ovarian cancer. After 18 CSCT treatments for cancer growing on the inside of her peritoneum (the membrane lining separating the internal organs from the ribs), April was judged free of cancer by her oncologist.
Beating the Survival Odds
When Maggie, age 53, was diagnosed with colon cancer that had spread to her liver, her oncologist told her there was no treatment available and he gave her 12 to 18 months to live. In fact, three different surgeons at two hospitals gave her the same dismal prognosis.
The previous year (1995), she had undergone surgery to remove a tumor the size of an orange from her abdomen. Maggie's doctor said the cancer was "localized, non-invasive," and not likely to spread; as such, it did not require chemotherapy, her oncologist said. Once every three months, Maggie underwent follow-up blood tests to monitor cancer markers; she had a CT scan, followed by an ultrasound. It was in one of these follow-ups that the doctor discovered the cancer had in fact spread to her liver. He told her:
"There's nothing we can do."
Maggie felt constant pressure around her midriff from her swollen liver and colon; when she inhaled there was pain and pressure—"like a stitch." Although she was tired all the time and went to bed at seven in the evening, Maggie never gave up hope for a successful treatment.
She got on a plane and flew from Ontario, Canada, to the Bahamas, where she checked in at the Immuno-Augmentative Therapy Center (IATC) in Freeport. IATC was founded in 1977 by alternative cancer treatment pioneer Lawrence Burton, Ph.D.
Today, IATC's medical director, John Clement, M.D., works closely with the Center for Cell Specific Cancer Therapy in Santo Domingo, both taking and sending referrals. "We can control the growth of cancer at IATC, but we can't seem to get rid of the basic, underlying cancer itself in a number of cases," says Dr. Clement. After gaining improvements at IATC, Maggie went to Santo Domingo to complete her cancer reversal.
"The two therapies together are a must," says Maggie. The CSCT Center can effectively destroy the tumors while IATC "shows people how to keep their immune system in top shape." From her first day at the Center onwards, the air was full of positive talk about cancer reversal, Maggie noted. "In conventional cancer treatment hospitals, they only talk about how long you have to live; here they talk about how long until you get better. They can't save everybody's life, but they can save lots of people's lives."
During Maggie's initial CSCT scan, Dr. Ubiera identified eight sites of cancer cells. The next day, Dr. Ubiera began twice-daily treatments on Maggie; after one week, only one cancer spot remained, and after the second week, that spot disappeared and Maggie was judged to be free of cancer. All subsequent blood tests, taken monthly, have come back normal. When she came home, Maggie felt "tremendous energy." She returned to work full time, without pain, midriff pressure, or tiredness. "I just felt good."
However, Maggie knows that the struggle to rid her body of cancer is not fully finished. "CSCT kills cancer—there is no question about it. But you are still predisposed. There is a reason you got cancer in the first place. When you come home the cancer can come back very quickly, so you have to do everything you possibly can to build up your immune system so that it can cope with any new cancer cells."
Converting the Conventional
It is still too early in the history of the CSCT Center for its long-term success rate to be known. "But the short-term results seem excellent," offers Dr. Clement. "Their device seems to be working. I've been there and seen the patients. Their operation is extremely ethical. If they can't help you, they don't accept you."
One of the additional advantages of CSCT may be found in its ability to treat brain cancers, Dr. Clement says. Brain cancers are highly resistant to chemotherapy drugs; a drug must cross the usually impermeable blood/brain barrier to get into cancerous brain tissue.
"That's why conventional treatment of brain cancer is very, very poor," comments Dr. Clement. "CSCT is not given via the blood but rather through magnetic waves, which can directly influence brain tumors. The fact that CSCT has any control or effect at all on brain tumors is remarkable and an important aspect of the Center's work. Another important feature is that the treatment is not invasive, harmful, or repressive of the patient's immune system."
The Center has an unusual pricing policy for treatment. They charge a flat fee of $20,000 (U.S.) regardless of how many treatment sessions are required. There are no additional charges, other than room and board, which Center patients secure in Santo Domingo. Those who are judged (through a strict means test) as unable to meet the treatment fee are eligible for treatment at a lower rate or at no charge at all, says Reynolds. "We have a flexible policy on fees. We never turn anybody away because they don't have enough money," Reynolds adds.
To put this in context, a typical conventional cancer treatment, from diagnosis to death, can often cost an insurance company $350,000. Once insurers start reimbursing for CSCT, the cost-savings should be unassailable, Reynolds states.
The Center's physicians are upbeat about the prospects for long-term success with CSCT. Grisel Canahuate Rodriguez, M.D., comments: "I have seen patients who have been treated with chemotherapy and radiation. The difference here is we are trying to find a more positive way to treat people without having all the side effects and destroying their immune system. Although it is still in its experimental stages, CSCT could make a difference in cancer treatment and should be considered by conventional doctors."
The Mechanics of a Revolutionary Cancer Treatment
Put most simply, the CSCT-200 destroys cancer cells by targeting them with manipulable magnetic energy, says Reynolds. The product of eight years of concentrated research and development by its inventors, Bob Scarbrough and Jim Claxton, both from Tennessee, the CSCT-200 consists of a donut-shaped ring or collar containing two types of magnets.
First, there is an array of low-strength permanent magnets, creating a steady electromagnetic field. Second, there is an electromagnetic coil passing through this array. This can be crudely pictured as an egg-shaped energy aura. As an electric current passes through the coil, it creates a dynamic, varying electromagnetic field around the coil, and this dynamic field (also egg-shaped) interacts with the static field emanating from the permanent magnets.
The result is a complex interacting electromagnetic field, says Reynolds. The CSCT-200 is designed to enable the operator to adjust or manipulate this field, somewhat like fine-tuning a radio. You can use electricity to change the shape of the complex electromagnetic field simply by changing the dial setting. This fact explains why the device's core technology in scientific jargon is called a frequency-modulated, pulsed electromagnetic field, says Reynolds.
The pulsing comes from the 60-Hertz electric current that enters the electromagnet in regular bursts at the rate of 60 times per second. Frequency modulation is an electronics term that means the sound vibration (or wave) can be adjusted in terms of the size of the wave and its duration. This effect is roughly akin to a mute being placed over and removed from a trombone.
Additionally, by altering the electric current, you can reverse the polarity of the permanent magnets, from north to south and back again, as needed. This polarity reversal of the electromagnetic field can be done in regular cycles (i.e., north, south, north, south, etc.), says Reynolds.
The "killing agent" in the CSCT-200 is the precisely-focused complex electromagnetic field. "Frequency, magnitude [size], and time are the three intervals that you coordinate in the matrix to achieve the maximum effect," says Richard Liang, Ph.D., the resident physicist at the Center for Cell Specific Cancer Therapy.
Will the CSCT-200 Avoid the Fate of the Rife Frequency Generator?
The CSCT-200 is not the first revolutionary cancer device based on energy, frequency, and electromagnetic waves, but it may be the first to survive the ravages of the FDA, American Medical Association, American Cancer Society, and other enemies of effective alternative cancer cures.
Back in the 1920s, American inventor Raymond Royal Rife of San Diego, California, developed a sophisticated microscope capable of examining live specimens, a technical feat still beyond the reach of today's electron microscopes. Rife's microscope enabled him to study a realm of biology never before seen close up—the world of viruses and living cancer cells.
Rife also figured out a way to kill cancer cells using electronic frequencies, using a device he called the Frequency Generator. After three months of daily treatment with the Rife device, 14 out of 16 "incurable" terminal cancer patients were declared clinically cured and in good health by a staff of five M.D.s.
When word of Rife's breakthrough got out, the conventional medical authorities closed ranks and began to discredit him. The American Cancer Society refused to acknowledge his clinical study, the American Medical Association (AMA) threatened to revoke the licenses of doctors using the device, and the FDA outlawed it.
The story has an even darker side. According to Barry Lynes and John Crane in The Cancer Cure That Worked! (Marcus Books, 1987), in the late 1930s, Morris Fishbein, M.D., then president of the AMA, first tried to buy into the Rife device by becoming an investor. When Rife refused, Dr. Fishbein used all his political power to persecute Rife and to organize a disastrous court case against Rife in 1939.
The inventors of CSCT-200 were "inspired" by what Rife did with frequency and electricity, says Richard Liang, Ph.D., the physicist at the Center for Cell Specific Cancer Therapy. "Our machine is not an expansion or improvement of the Rife device, but his idea is the major motif in our process." The CSCT inventors "found a way of using much less power and in a less complicated but more efficient form than Rife did, and with instant feedback on results," adds Center co-director Michael Reynolds. It is hoped that CSCT-200 will escape the outrageous fate of Rife's frequency generator by its inventors having located it outside the jurisdiction of U.S. medical authorities.